Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 13/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769676 | 0.86 | KEAP1 (0.50) | KEAP1NFE2L2CMA1CYP2A6PRSS1 | |
| SCHEMBL10443345 | 0.83 | CYP2A6 (0.43) | KEAP1NFE2L2CMA1CYP2A6PRSS1 | |
| SCHEMBL20769674 | 0.83 | CMA1 (0.49) | KEAP1NFE2L2CMA1PRSS1PRSS2 | |
| SCHEMBL20769662 | 0.81 | KEAP1 (0.52) | KEAP1NFE2L2CMA1CYP2A6PRSS1 | |
| SCHEMBL10443833 | 0.80 | F9 (0.42) | KEAP1NFE2L2CMA1CYP2A6PRSS1 | |
| SCHEMBL5469039 | 0.80 | ALOX5 (0.50) | CMA1CYP2A6MAPT | |
| SCHEMBL12315021 | 0.78 | CMA1 (0.59) | KEAP1NFE2L2CMA1CYP2A6PRSS1 | |
| SCHEMBL16753110 | 0.78 | KEAP1 (0.49) | KEAP1NFE2L2CMA1CYP2A6PRSS1 | |
| SCHEMBL3126894 | 0.76 | CMA1 (0.50) | KEAP1NFE2L2CMA1CYP2A6PRSS1 | |
| SCHEMBL15211671 | 0.76 | HSD17B10 (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7235569-B2 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH (US) | 2007-06-26 | — | — | US | disclosed |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | TPH1, TPH2, HTR3A | KEAP1 2597/4885NFE2L2 2528/4885CMA1 3030/4885 |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | TPH1, TPH2, HTR4 | KEAP1 2566/4885NFE2L2 2814/4885CMA1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.